Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TT5
- Development stage
- Phase 1
- Lead developer
- Tafalgie Therapeutics
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
TT5 is an investigational drug developed by Tafalgie Therapeutics. It is currently undergoing a First-in-Human, three-part, double-blind, randomized, placebo-controlled, single and multiple ascending dose study. The primary objectives of this study are to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TT5 in both healthy volunteers and surgical patients. The drug is administered via direct intravenous injection.
- Other names
- TAFA4 protein derivativeTAFA-4 protein derivativeTAFA 4 protein derivativeTAFA4-based peptideTAFA-4-based peptideTAFA 4-based peptide
02
Targets
TAFA4
Beyond the preview
Go deeper on TT5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TT5.